ABBV vs CRWD: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and CrowdStrike Holdings, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-09.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
CrowdStrike Holdings, Inc. · Technology
$191.12
+32.7% upside to fair value
Grade B
QuantHub Verdict
CRWD has more upside to fair value
(+32.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
CRWD |
| Current Price |
$261.07 |
$191.12 |
| Fair Value Estimate |
$264.30 |
$253.64 |
| Upside to Fair Value |
+1.2%
|
+32.7%
|
| Market Cap |
$461.3B |
$194.6B |
| Forward P/E |
128.0x
|
-4023.6x
|
| EV / EBITDA |
31.0x
|
570.3x
|
| Price / Sales |
7.3x
|
38.2x
|
| Price / FCF |
22.1x
|
134.0x
|
| Revenue Growth YoY |
+12.4%
|
+25.6%
|
| Gross Margin |
70.7%
|
75.0%
|
| Operating Margin |
27.6%
|
-3.9%
|
| Return on Equity |
68.0%
|
-0.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
0.75%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
CrowdStrike Holdings, Inc. operates in the technology sector, specifically in software infrastructure, providing cybersecurity solutions. The business quality is medium due to its strong revenue growth of 25.6% in the most recent quarter and impressive earnings growth of 125.2% in the same period, indicating effective scaling and operational leverage. However, profitability metrics remain challen…
Accumulation Zones
| Metric |
ABBV |
CRWD |
| Zone Low |
$198.23 |
$190.23 |
| Zone High |
$224.66 |
$215.59 |
| In Buy Zone? |
No
|
Yes
|